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Aim: Intrathyroid metastases are uncommon in cytology practice. We report a case of metastatic lesion in the thyroid from breast 
carcinoma which was recognized in a fine-needle aspiration (FNA) biopsy and confirmed by immunohistopathology. In addition, 
we provide an overview of the literature describing similar cases. Study design: The patient was a 54-year old woman with a large, 
multinodular goiter and bilaterally enlarged lymph nodes in the supraclavicular areas. Fourteen years earlier she had undergone 
radical mastectomy followed by chemio- and radiotherapy due to a breast carcinoma. Results: FNA of the thyroid nodules showed 
a metastatic breast carcinoma and was followed by total strumectomy and lymphadenectomy. Histological reassessment of the 
surgical thyroid specimens as well as the neck lymph nodes revealed multiple breast metastases. This was strongly confirmed by im-
munohistochemical examinations, which revealed a positive staining for: CKMNF 116, CK7, CEA as well as for ER, PgR and 
HER2, and a negative staining for: CK20, thyroglobulin, TTF1, calcitonin, and chromogranin. Conclusion: Every new aggregate 
in the thyroid in patients with even a long-term history of cancer should be considered as potentially metastatic until proved other-
wise. FNA could be helpful in the diagnosis of thyroid metastatic lesion, but it should be confirmed by immunohistopathology.
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Altho�gh� the possibility of a metastasis from non-
thyroid cancers to the thyroid gland is rare� it sho�ld 
be taken into acco�nt� beca�se it is not as infreq�ent 
as widely believed. Generally� the primary t�mor is fo�nd 
in the kidneys� gastrointestinal system �like the esopha-
g�s� stomach or colon�� bronchi� or breast [���5]. 
Several reports have indicated the iris� parotid� �ter�s� 
leiomyosarcoma� oropharynx sq�amo�s cell carcinoma 
or ling�al sq�amo�s cell carcinoma as the less common 
origin of the metastatic thyroid lesions [�� ��6].
The occ�rrence of metastases depends on the 
character of the material analyzed. Commonly� me-
tastases to the thyroid gland are identified �pon 
a�topsy and according to vario�s reports� the val�e 
ranges from �.�5���.�% [�� 5� 7� �6]. Very few st�-
dies mention metastatic disease in clinical material� 
where it is estimated at ���% of all malignant t�mors 
diagnosed in the thyroid [�]. With regard to its origin� 
the most common primary t�mor site seems to be the 
kidney [���� 7� 8� ��].
Breast cancer is less freq�ent� b�t a new thyroid 
mass sho�ld be considered as a metastasis of breast 
carcinoma in any patient with a former history of this 
malignancy. Breast metastatic cancer is eval�ated 
at ca. �6.� to ��.�% in postmortem examinations� 
b�t only �.���.�% cases are enco�ntered in clinical 
papers [�� 8� ��]. Metastatic disease of the thyroid 
co�ld present as single nod�le� m�ltinod�lar goiter 
or thyroiditis [�� ��].
Altho�gh fine needle aspiration biopsy of the thy-
roid lesions is helpf�l in the thyroid metastasis nod�les 
[�7���]� histopathological verification and imm�no-
histochemical �IHC� examination are recommended 
for the final diagnosis [�7���].
Especially� IHC staining proves very �sef�l in dif-
ferentiation diagnosis between primary thyroid t�mors 
on the one hand and metastatic breast carcinoma 
on the other. In case of metastatic thyroid t�mo�r IHC 
staining for calcitonin �CT�� thyroglob�lin �TG� and 
thyroid transcription factor � �TTF-�� is negative [��� 
��]. On the contrary� CKMNF ��6� cytokeratin 7 �CK7�� 
carcinoembryonic antigen �CEA� and mammoglob�-
lin � �MGB�� are specific and sensitive markers and 
sho�ld be positive in metastatic breast cancer [�5]. 
In addition� estrogen and progesterone receptors 
�ER� PgR� as well as herceptin receptor �HER�� might 
be eval�ated in metastatic breast cancer [�6]. 
In this paper we report a case of metastatic le-
sion in the thyroid from breast carcinoma which was 
s�spected in fine needle aspiration �FNA� biopsy and 
confirmed by post-operative histopathology and im-
m�nochemistry. In addition� we provide an overview 
of literat�re describing similar cases. 
CASE REPORT
A 5�-year-old woman with enormo�s m�ltinod�lar 
goiter categorized as IV according to World Health 
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Organisation �WHO� was admitted to o�r hospital after 
complaining of a dyspnoea and stridor. 
Fo�rteen years earlier she had been diagnosed with 
carcinoma in the left breast classified as d�ctal-lob�lar 
mammary carcinoma �T�N�bM�� for which she had 
�ndergone radical mastectomy and limfadenectomy 
with s�bseq�ent chemiotherapy in accordance with 
Ansfield’s scheme �cyclophosphamide� methotrexate� 
fl�oro�racil� vincristine�and prednisone� and radiation 
therapy �5� Gy�. At the same time� in the right breast 
dysplasia occ�rred. The disease was asymptomatic for 
6 years� and after that period developed skeletal metas-
tases for which the patient �nderwent radiotherapy and 
for the next fo�r years she received Nolvadex. Moreover� 
one year later metastases in the region of cicatrice oc-
c�rred. The patient received brahytherapy to the whole 
�pper-left side of the chest where the cicatrice was 
sit�ated by external beam irradiation aiming at �� Gy. Af-
terwards� she received doxor�bicin �Adriblastin�� vinorel-
bine �Navelbine� and consec�tive radiation therapy was 
administered in the region of the left breast. F�rthermore� 
as regards systemic therapy� the patient was controlled 
by hormonal therapy �sing hormone-blocking medica-
tions� s�ch as anastrozol� �Arimidex�. At the same time� 
metastatic disease in the s�prarenal gland was s�spec-
ted. No f�rther rec�rrences were noticed for two years. 
When the patient was admitted to o�r instit�tion� 
thyroid �ltrasonography �USG� showed heterogeno�s 
m�ltinod�lar goiter with a total vol�me of 78 ml. Bilate-
rally� in s�praclavic�lar areas� two packets of lymph 
nodes �probably metastatic� were noticeable. These 
pre-operative investigations with USG and FNA strongly 
s�ggested or verified metastases from the breast cancer. 
A techneti�m-��m bone scintigraphy showed 
m�ltiple metastases which were located in the head 
of the h�meral bone� the left ili�m� the right femoral 
bone as well as in the lower s�bscap�lar angle of the 
right scap�la and sacr�m on the S� level. The pancreas 
and spleen revealed no changes. Mammography of the 
right breast showed no abnormalities. 
According to investigations� the patient was e�thyroid 
�ser�m TSH� fT� and fT� levels in normal range� and a to-
tal thyroidectomy was performed� res�lting in a histologi-
cal diagnosis as metastatic breast carcinoma infiltrating 
the s�rro�nding blood vessels. At the time of s�rgery 
bilateral neck limphadenectomy was exec�ted and histo-
logical reassessment of the s�rgical specimens of lymph 
nodes revealed m�ltiple breast metastases. 
Conseq�ently postoperative specimens were taken 
for IHC stains� which showed positive res�lts for: CK-
MNF ��6 �+�� CK7 �++�� CEA �+� and MGB� �++�� and 
negative staining for: CK��� TG� TTF�� CT� chromogranin 
�Fig. � a� b� � a� b�. IHC staining confirmed the meta-
stases from the breast cancer. In addition� IHC staining 
for expression of progesterone and estrogen receptors 
�ER and PgR� as well as herceptin HER� showed positive 
reaction �Fig. �� � a� b� 5 a� b� c�.
Post-operatively the patient received L-thyroxin 
in a daily dose of ��5 µg. After s�rgery the plasma level 
of Ca-�5.� increased� and three� fo�r and five months 
later amo�nted to ��6.� U/ml� ���.7 U/ml� ���.� U/ml� 
appropriately �norm: �.����.� U/ml�.
Unfort�nately� in the same year metastases to the 
liver were fo�nd �o�r earlier investigations demon-
strated only two hepatic cysts in the right lobe of the 
liver and steatosis�.
a
b
Fig. 1. IHC stains of the thyroid sections: �a� IHC staining for TG 
�×���; �b� IHC stating for TTF� �×��� 
a
b
Fig. 2. �a): IHC staining for CK7 �×���. �b): IHC staining for mam-
moglob�lin �Mam_�A5; stain ×���
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Regrettably� other examinations showed metasta-
ses to the right l�ng. According to these investigations 
chemiotherapy was carried o�t one more time �Mitro-
xanton� Taxotere and Xeloda� b�t beca�se of cance-
ro�s cachexia and no possibilities of chemiotherapy� 
she was directed to the O�tpatient Clinic Against Pain. 
She died three years later.
In present st�dy� metastasis to the thyroid gland 
occ�red �� years after diagnosis of the primary di-
sease. The thyroid deposit was the third site of distant 
metastases. 
DISCUSSION
Metastatic breast cancer will ca�se symptoms that 
depend on the location of metastasis. Most common 
site of metastasis incl�de: bone� liver� l�ng and brain. 
In the thyroid it is �s�ally present as single or m�ltiple 
nod�les� b�t also enlarged nod�lar goiter or thyroiditis 
[�� ��]. Most commonly� patients reported the feeling 
of press�re and enlarged neck circ�mference. There-
fore some patients with metastatic lesion presented 
hoarseness� dysphagia� stridor and dyspnea� b�t 
respiratory problems are less freq�ent symptoms and 
occ�r mostly when the disease develops q�ickly [�� �].
Unq�estionably� the thyroid gland has an affl�ent 
blood s�pply close to 56� mL/��� g tiss�e/min� which 
is denoted to be second only to the adrenal gland [�]. 
Despite that� this gland is a rare site for metastatic 
disease to develop [�� ��].
Based on these data� we recommended that the 
diagnosis of metastatic disease o�ght to be s�spected 
in patients with even a remote history of cancer� no mat-
ter how remote that history is. Every new aggregate in the 
thyroid sho�ld be considered as potentially metastatic �ntil 
proved otherwise. A differential diagnosis sho�ld be car-
Fig. 3. FNA of the thyroid gland �H&E stain × ���. Cl�ster of ma-
lignant cells with enlarged n�clei which have irreg�lar chromatin 
str�ct�re. Scant cell cytoplasm. Individ�al cells contain endo-
plasmatic vac�oles with centrally condensed m�c�s
a
b
Fig. 4. �a): Histologic section from metastatic lesion in the thy-
roid from breast cancer �H&E stain × ���. �b): Histologic section 
from primary t�mor in the breast showing infiltrating mammary 
cancer �H&E stain x���
a
b
c
Fig. 5. IHC staining for ER ���x� �a� and PgR ���x� �b� as well 
as for HER � ���x� �c� in the metastatic lesion in thyroid from 
breast cancer. Positive reaction is observed in over 75% of n�clei 
cells eval�ated
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ried o�t in the case of m�ltinod�lar goiter as well as benign 
thyroid nod�les. Gerges et al. reported that breast and l�ng 
cancers are the most common diseases metastating to the 
thyroid gland in most a�topsy series in contrast to clinical 
series� where the most freq�ent is renal cell carcinoma [5]. 
Unq�estionably� the know ledge of the whole clinical his-
tory of the patient is very helpf�l for making this diagnosis. 
In o�r case� the thy roi dectomy was performed �� years 
after the initial diagnosis.
Upon reviewing the literat�re the involvement of the 
thyroid generally becomes apparent or at the same time 
or from a few months to �� years after the diagnosis 
of the primary t�mor [�� 5� ��� ��� �5� �7� �8� ��� ��]. 
O�r data showed that these intervals co�ld be even 
longer. In the association of widespread metastatic 
lesion� �s�ally the clinical manifestation of metastatic 
disease has no importance. In addition� the long interval 
between the original primary t�mo�r and s�bseq�ent 
thyroid metastases s�bmitted a diagnostic problem.
Thyroid metastases from breast cancer are �ncom-
mon b�t ro�tine �se of fine needle aspiration co�ld 
help detect it more freq�ently [��]. FNA biopsy plays 
an important role in the whole diagnostic process� 
since it may confirm a clinical s�spicion. What is more� 
it is a safe� inexpensive and simple proced�re [5]. 
The patient described �nderwent preoperative 
FNA� which s�ggested metastatic thyroid lesion from 
the breast cancer.
Breast metastatic carcinoma to the thyroid is �n-
common phenomena in cytology practice and may 
give a diagnostic dilemma partic�larly in the presence 
of some morphologic similarities with primary thyroid 
lesions. So histopathology res�lts sho�ld be confirmed 
by IHC examinations.
TG and calcitonin CT as well as TTF� may be �sef�ll 
markers for disting�ish breast metastatic lesions from 
primary thyroid lesions [��� ��]. 
Normal thyroid follic�lar cells are stained strongly 
for TG protein� which allows the TG expression ob-
tained to confirm the histogenesis of nonmed�llary 
carcinomas comprising thyroid cancer of follic�lar 
cell origin [��].
On the other hand� CT and its mRNA is mostly con-
sidered as the most important specific marker of para-
follic�lar cells �C-cells� and is considered as obli gatory 
for the diagnosis of med�llary carcinomas derived from 
C-cells in h�mans. F�rthermore� IHC staining for mRNA-
CT and peptides are detected in all C-cell lesions [��]. 
Metastatic t�mors in the thyroid gland showed negative 
staining for both TG and CT in the metastatic cells. 
Moreover� TTF-� reg�lates the transcription of thy-
roid-specific genes in thyroid follic�lar cells and acti-
vates Tg and TPO �thyroperoxidase� gene transcription 
in thyroid carcinomas. The overexpression of TTF� co�ld 
be an �sable marker not only for follic�lar cell t�mors and 
b�t also for C cells and med�llary thyroid carcinomas .
The next marker which was negative in patient de-
scribed was chromogranin A �CHGA�. It is secreted 
by a great variety of peptide-prod�cing endocrine neo-
plasms: pheochromocytoma� parathyroid adenoma� med-
�llary thyroid carcinoma� carcinoids� oat-cell l�ng cancer� 
pancreatic is let-cell t�mo�r and aortic body t�mor� 
so it can be helpf�l for excl�sion C-cells carcinoma [�7]. 
To diagnose a primary carcinoma metastasizing 
to the thyroid many IHC markers sho�ld be eval�ated. 
There are several factors that m�st be taken into 
consideration to confirm the thyroid metastases from 
the breast cancer. The most �sef�l seem to be the 
following: MGB�� CEA� ER� PgR� HER� [�5� �6� �8].
MGB� is expressed in normal h�man breast� �ter�s 
and salivary gland; b�t over expression of MGB� is seen 
in breast t�mo�r. In case st�died IHC for MGB� showed 
moderate staining in 7�% of t�mo�r cells.
Otherwise CEA is a t�mor marker widely �sed for 
eval�ating patients with breast cancer and seems 
to be associated with a poor prognosis [�5].
In addition� imm�nohostochemical expression 
of both estrogen and progesterone receptors as well 
as transmembrane protein HER� in postoperative thy-
roid specimens from patient st�died were investigated 
and showed strong positive reaction �over 75% of cells 
n�clei� for ER and PgR and moderate positive reaction 
for HER�. These three markers are rather prognostic 
and predictive one of response therapies� both in early 
and metastatic breast cancer [�6� �����].
IHC analysis revealed also mode rate reactivity for 
CK7 �++�� in spite of negative reaction for CK��. The 
last one is a prominent marker rather for intestinal and 
gastric epitheli�m� �rothelial �mbrella cells and Merkel 
cells of epidermis as well as in the thym�s� bronch�s� 
gallbladder and prostate gland. 
From blood markers most often �sed to follow pa-
tients with advanced breast cancer or its rec�rrence 
after treatment� CA�5.�� CEA and CA�7.�� indicated 
high ser�m levels in patient st�died [�5].
To concl�de� FNA and IHC stai nings might to ascer-
tain whether the thyroid nod�le is a primary or a meta-
static lesion.
Very few st�dies indicated the type of meta-
static breast carcinoma �Table�. Loo et al.� ���� [�7] 
showed ne�roendocrine breast carcinoma to be the 
origin of the metastatic thyroid lesion . Owens et al.� 
���5 [�8] showed that infiltrating mammary carcinoma 
co�ld ca�se metastatic disease. Gong et al.� ���5 [��] 
described metastastic breast carcinoma as a mesen-
chymal or sq�amo�s cell carcinoma connected with 
d�ctal carcinoma. In the literat�re there was also a case 
where breast carcinoma metastatic to follic�lar variant 
of papillary thyroid carcinoma developed [��].
F�rthermore� USG and mammography sho�ld 
be performed where there is any s�spicion of thyroid 
cancer or breast cancer d�e to the possibility of both 
coexisting.
Based on the reported case we concl�de that the 
diagnosis of metastatic disease o�ght to be s�spected 
in patients with even distant history of cancer� no mat-
ter how remote that history is. A review of the literat�re 
showed that metastases to the thyroid gland does not 
depend on histological type of the breast carcinoma. 
In view of the above� we ded�ce that every new aggre-
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gate in the thyroid sho�ld be considered as potentially 
metastatic �ntil proved otherwise. 
Table. Reports of metastases to the thyroid gland from breast carcinoma 
diagnosed by FNA
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Gong et al., 
2005 [20]
+ 2 yrs - No data Mesenchymal and/
or squamous cell com-
ponents associated 
with ductal cancer
Loo et al., 
2003 [17]
+ 8 yrs + Antiestrogen 
therapy
Neuroendocrine breast 
cancer
Owens et al., 
2005 [18]
+ 5 yrs + Paliative Infiltrating mammary 
cancer
Yu et al.,
2009 [22]
+ No data - Partial thy-
roidectomy
Breast cancer meta-
static to follicular vari-
ant of papillary thyroid 
cancer
Note: IHC — immunohistochemical staining.
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